Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi

episode

Blood Cancer Talks not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Bears aren't ruling out Caleb Williams against Eagles, but will he play? (Hour 1) 41 min · 22 Sep 2026 · Rahimi & Grote Show

Week 3 Waivers + Someone to Blame - Fantasy Football Podcast for 9/22 52 min · 22 Sep 2026 · Fantasy Footballers - Fantasy Football Podcast

First Date Follow Up: She Thought Their Date Was Perfect… Until He Found Out She Was MARRIED! 16 min · 22 Sep 2026 · First Date Follow Up - The Jubal Show

Neville Gallimore talks Bears' 9-3 loss to Vikings, Caleb Williams' injury 18 min · 22 Sep 2026 · Rahimi & Grote Show

Bears aren't ruling out Caleb Williams against Eagles, but will he play? 11 min · 22 Sep 2026 · Rahimi & Grote Show

Trump Defends Iran War, Apple's New Fitness Tracker, More 6 min · 22 Sep 2026 · Bloomberg News Now

Report any issue

Source

Recorded27 Mar 2024

Publisherfeeds.transistor.fm ↗

Handlerec:6840562

Show notes

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4:https://www.youtube.com/watch?v=VSjdGeeXb40

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in